Lukas Scheibler - 28 Jan 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
CHIEF INNOVATION OFFICER
Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Issuer symbol
APLS
Transactions as of
28 Jan 2022
Transactions value $
-$72,208
Form type
4
Filing time
01 Feb 2022, 16:58:09 UTC
Previous filing
24 Jan 2022
Next filing
10 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Tax liability -$24.8K -642 -1.15% $38.59 55.1K 28 Jan 2022 Direct F1
transaction APLS Common Stock Sale -$47.4K -1.23K -2.24% $38.47 53.9K 31 Jan 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares used to cover tax withholding on a Restricted Stock Unit release.
F2 This is a scheduled sale from 10B5-1 trading plan.